Satish Kumar Nandakumar
Hematology/Oncology, Boston Children's Hospital
Dr. Nandakumar received his PhD in biomedical sciences from the University of Tennessee Health Science Center in 2014. He received training in hematopoiesis and the development of gene delivery methods into hematopoietic stem cells using lentiviral vectors. During his graduate research he studied the role of transcription factor GATA2 in mouse hematopoietic stem cells, as well as myeloid leukemia. Dr. Nandakumar is currently a postdoctoral researcher at Boston Children’s Hospital in affiliation with Harvard Medical School. He uses human genetic studies, called genome wide association studies (GWAS), to identify genes and gene variants affecting production of human blood cells. He also develops approaches to modify hematopoietic stem cells (HSCs) for the treatment of blood disorders. He has published several articles in the top journals in the field, including Cell, PNAS and Experimental Hematology. He has received prestigious awards from the National Hemophilia Foundation and American Society of Human Genetics.
Hematopoietic stem cell, Hematopoiesis, Erythropoiesis, Cellular differentiation, CRISPR/Cas9, Gene therapy, Gene regulation, Transcription factors, Enhancers, Genetic blood disorders, Sickle cell anemia, Thalassemia, Genetic variation.